An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases
ABSTRACT Influenza, as well as other respiratory viruses, can trigger local and systemic inflammation resulting in an overall “cytokine storm” that produces serious outcomes such as acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). We hypothesized that gene therapy platforms cou...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2025-02-01
|
| Series: | mBio |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/mbio.03387-24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096526500888576 |
|---|---|
| author | Kari Ann Shirey John Joseph Lynda Coughlan Haye Nijhuis Alan W. Varley Jorge C. G. Blanco Stefanie N. Vogel |
| author_facet | Kari Ann Shirey John Joseph Lynda Coughlan Haye Nijhuis Alan W. Varley Jorge C. G. Blanco Stefanie N. Vogel |
| author_sort | Kari Ann Shirey |
| collection | DOAJ |
| description | ABSTRACT Influenza, as well as other respiratory viruses, can trigger local and systemic inflammation resulting in an overall “cytokine storm” that produces serious outcomes such as acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). We hypothesized that gene therapy platforms could be useful in these cases if the production of an anti-inflammatory protein reflects the intensity and duration of the inflammatory condition. The recombinant protein would be produced and released only in the presence of the inciting stimulus, avoiding immunosuppression or other unwanted side effects that may occur when treating infectious diseases with anti-inflammatory drugs. To test this hypothesis, we developed AdV.C3-Tat/HIV-Box A, an inflammation-inducible cassette that remains innocuous in the absence of inflammation but releases HMGB1 Box A, an antagonist of high mobility group box 1 (HMGB1), in response to inflammatory stimuli such as lipopolysaccharide (LPS) or influenza virus infection. We report here that this novel inflammation-inducible HMGB1 Box A construct in a non-replicative adenovirus (AdV) vector mitigates lung and systemic inflammation therapeutically in response to influenza infection. We anticipate that this strategy will apply to the treatment of multiple diseases in which HMGB1-mediated signaling is a central driver of inflammation.IMPORTANCEMany inflammatory diseases are mediated by the action of a host-derived protein, HMGB1, on Toll-like receptor 4 (TLR4) to elicit an inflammatory response. We have engineered a non-replicative AdV vector that produces HMGB1 Box A, an antagonist of HMGB1-induced inflammation, under the control of an endogenous complement component C3 (C3) promoter sequence, that is inducible by LPS and influenza in vitro and ex vivo in macrophages (Mϕ) and protects mice and cotton rats therapeutically against infection with mouse-adapted and human non-adapted influenza strains, respectively, in vivo. We anticipate that this novel strategy will apply to the treatment of multiple infectious and non-infectious diseases in which HMGB1-mediated TLR4 signaling is a central driver of inflammation. |
| format | Article |
| id | doaj-art-90f57e300d364945aba05cbaebc0dd84 |
| institution | Kabale University |
| issn | 2150-7511 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | mBio |
| spelling | doaj-art-90f57e300d364945aba05cbaebc0dd842025-02-05T14:00:48ZengAmerican Society for MicrobiologymBio2150-75112025-02-0116210.1128/mbio.03387-24An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseasesKari Ann Shirey0John Joseph1Lynda Coughlan2Haye Nijhuis3Alan W. Varley4Jorge C. G. Blanco5Stefanie N. Vogel6Department of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, Maryland, USASigmovir Biosystems Inc., Rockville, Maryland, USADepartment of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, Maryland, USADepartment of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, Maryland, USAIndependent Researcher, Plano, Texas, USASigmovir Biosystems Inc., Rockville, Maryland, USADepartment of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, Maryland, USAABSTRACT Influenza, as well as other respiratory viruses, can trigger local and systemic inflammation resulting in an overall “cytokine storm” that produces serious outcomes such as acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). We hypothesized that gene therapy platforms could be useful in these cases if the production of an anti-inflammatory protein reflects the intensity and duration of the inflammatory condition. The recombinant protein would be produced and released only in the presence of the inciting stimulus, avoiding immunosuppression or other unwanted side effects that may occur when treating infectious diseases with anti-inflammatory drugs. To test this hypothesis, we developed AdV.C3-Tat/HIV-Box A, an inflammation-inducible cassette that remains innocuous in the absence of inflammation but releases HMGB1 Box A, an antagonist of high mobility group box 1 (HMGB1), in response to inflammatory stimuli such as lipopolysaccharide (LPS) or influenza virus infection. We report here that this novel inflammation-inducible HMGB1 Box A construct in a non-replicative adenovirus (AdV) vector mitigates lung and systemic inflammation therapeutically in response to influenza infection. We anticipate that this strategy will apply to the treatment of multiple diseases in which HMGB1-mediated signaling is a central driver of inflammation.IMPORTANCEMany inflammatory diseases are mediated by the action of a host-derived protein, HMGB1, on Toll-like receptor 4 (TLR4) to elicit an inflammatory response. We have engineered a non-replicative AdV vector that produces HMGB1 Box A, an antagonist of HMGB1-induced inflammation, under the control of an endogenous complement component C3 (C3) promoter sequence, that is inducible by LPS and influenza in vitro and ex vivo in macrophages (Mϕ) and protects mice and cotton rats therapeutically against infection with mouse-adapted and human non-adapted influenza strains, respectively, in vivo. We anticipate that this novel strategy will apply to the treatment of multiple infectious and non-infectious diseases in which HMGB1-mediated TLR4 signaling is a central driver of inflammation.https://journals.asm.org/doi/10.1128/mbio.03387-24TLR4MD-2HMGB1Box AinfluenzaLPS |
| spellingShingle | Kari Ann Shirey John Joseph Lynda Coughlan Haye Nijhuis Alan W. Varley Jorge C. G. Blanco Stefanie N. Vogel An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases mBio TLR4 MD-2 HMGB1 Box A influenza LPS |
| title | An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases |
| title_full | An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases |
| title_fullStr | An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases |
| title_full_unstemmed | An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases |
| title_short | An adenoviral vector encoding an inflammation-inducible antagonist, HMGB1 Box A, as a novel therapeutic approach to inflammatory diseases |
| title_sort | adenoviral vector encoding an inflammation inducible antagonist hmgb1 box a as a novel therapeutic approach to inflammatory diseases |
| topic | TLR4 MD-2 HMGB1 Box A influenza LPS |
| url | https://journals.asm.org/doi/10.1128/mbio.03387-24 |
| work_keys_str_mv | AT kariannshirey anadenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT johnjoseph anadenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT lyndacoughlan anadenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT hayenijhuis anadenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT alanwvarley anadenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT jorgecgblanco anadenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT stefanienvogel anadenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT kariannshirey adenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT johnjoseph adenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT lyndacoughlan adenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT hayenijhuis adenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT alanwvarley adenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT jorgecgblanco adenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases AT stefanienvogel adenoviralvectorencodinganinflammationinducibleantagonisthmgb1boxaasanoveltherapeuticapproachtoinflammatorydiseases |